Identifying Drug Candidates for Glioblastoma Treatment
Author Information
Author(s): Ntafoulis Ioannis, Koolen Stijn L. W., van Tellingen Olaf, den Hollander Chelsea W. J., Sabel-Goedknegt Hendrika, Dijkhuizen Stephanie, Haeck Joost, Reuvers Thom G. A., de Bruijn Peter, van den Bosch Thierry P. P., van Dis Vera, Gao Zhenyu, Dirven Clemens M. F., Leenstra Sieger, Lamfers Martine L. M.
Primary Institution: Erasmus University Medical Center
Hypothesis
Can a drug selection pipeline identify CNS-penetrant drug candidates for glioblastoma?
Conclusion
Omacetaxine mepesuccinate achieves brain tumor tissue concentrations exceeding its in vitro IC50 values in patient-derived glioblastoma cell cultures.
Supporting Evidence
- Omacetaxine mepesuccinate was selected based on its in vitro anti-glioma activity.
- The study utilized patient-derived xenograft models to assess drug delivery.
- Drug concentrations in brain tumor tissue were significantly higher than in vitro IC50 values.
Takeaway
This study shows that a drug called omacetaxine can reach high enough levels in brain tumors to potentially be effective against glioblastoma, a type of brain cancer.
Methodology
The study used a drug selection platform combining in vitro drug screening data and pharmacokinetic profiles, along with intracranial patient-derived xenograft models.
Limitations
The study's findings may not fully predict drug behavior in humans due to differences in metabolism between mice and humans.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website